Literature DB >> 29850177

Individualized clopidogrel suspension strategy coronary artery bypass surgery: what is the best choice?

Rafik Margaryan1, Michele Murzi1.   

Abstract

Entities:  

Year:  2018        PMID： 29850177      PMCID： PMC5949418          DOI： 10.21037/jtd.2018.03.76

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  4 in total

1.  Individualized strategy for clopidogrel suspension in patients undergoing coronary surgery: is it the best choice?

Authors:  Vito A Mannacio; Luigi Mannacio; Giovanni B Pinna; Carlo Vosa
Journal:  Eur J Cardiothorac Surg       Date:  2016-02-09       Impact factor: 4.191

2.  Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.

Authors:  Sean van Diepen; Valentin Fuster; Subodh Verma; Taye H Hamza; F Sandra Siami; Shaun G Goodman; Michael E Farkouh
Journal:  J Am Coll Cardiol       Date:  2017-01-17       Impact factor: 24.094

3.  2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations.

Authors:  Victor A Ferraris; Sibu P Saha; Julie H Oestreich; Howard K Song; Todd Rosengart; T Brett Reece; C David Mazer; Charles R Bridges; George J Despotis; Kanae Jointer; Ellen R Clough
Journal:  Ann Thorac Surg       Date:  2012-11       Impact factor: 4.330

4.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine
Journal:  Eur Heart J       Date:  2018-01-14       Impact factor: 29.983
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.